Cost-effectiveness analysis of topical treatments for actinic keratosis in the perspective of the Italian health care system

Giornale Italiano di Dermatologia e Venereologia

Volumn 145, Issue 5, 2010, Pages 573-581

  Colombo, G L ^a,b   Chimentp, S ^c   Matteo, S D I ^b   Fargnoli, M C ^d   Frascione, P ^e   Silipo, V ^e   Peris, K ^d  

^a UNIVERSITY OF PAVIA   (Italy)

^b SAVE Studi Analisi Valutazioni Economiche   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF L'AQUILA   (Italy)

^e SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

Author keywords

Actinic; Cost benefit analysis; Healt care costs; Keratosis

Indexed keywords

AMINOLEVULINIC ACID METHYL ESTER; DICLOFENAC; HYALURONIC ACID; IMIQUIMOD;

ACTINIC KERATOSIS; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE SYSTEM; HUMAN; PHOTODYNAMIC THERAPY; TREATMENT RESPONSE;

EID: 78650737759     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Olsen EA, Abemethy ML, Kulp-Shorten C, Callen JP, Glazer SD, Huntley A et al. A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol 1991, 24(5 Pt 1):738-43.
2. Peris K, Micantonio T, Piccolo D́, Fargnoli MC. Dermoscopic features of actinic keratosis. J Dtsch Dermatol Ges 2007;5:970-6.
3. Heaphy MR Jr, Ackerman AB. The nature of solar keratosis: a critical review in historical perspective. J Am Acad Dermatol 2000;43:138-50.
4. Ackerman AB, Mones JM. Solar (actinic) keratosis is a squamous cell carcinoma. Br J Dermatol 2006;155:9-22. (Pubitemid 43876387)
5. Marks R. Who benefits from calling a solar keratosis a squamous cell carcinoma? Br J Dermatol 2006; 155:23-6.
6. Lebwohl M. Actinic keratosis: epidemiology and progression to squamous cell carcinoma. Br J Dermatol 2003; 149:S31-33.
7. Stockfleth E, Ferrandiz C, Grob JJ, Leigh I, Pehamberger H, Kerl H; European Skin Academy. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol 2008; 18: 651-9.
8. Green A, Battistutta D. Incidence and determinants of skin cancer in a high-risk Australian population. Int J Cancer 1990;46:356-61.
9. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953;6:963-8.
10. Merk HF. Topical diclofenac in the treatment of actinic keratoses. Int J Dermatol 2007;46:12-8.
11. Fecker LF, Stockfleth E, Braun FK, Rodust PM, Schwarz C, Köhler A et al. Enhanced Death Ligand-Induced Apoptosis in Cutaneous SCC Cells by Treatment with Diclofenac/Hyaluronic Acid Correlates with Downregulation of c-FLIP. J Invest Dermatol 2010; 130:2089-2109.
12. Wolf JEJr,TaylorJR,TschenE, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001;40:709-13.
13. Rivers JK, Ariette J, Shear N, Guenther L, Carey W, PoulinY. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002;146:94-100. (Pubitemid 34158414)
14. Gebauer K, Brown P, Varigos G. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas J Dermatol 2003;44:40-5.
15. Pirard D, Vereecken P, Mélot C, Heenen M. Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses: a metaanalysis of the recent studies. Arch Dermatol Res 2005;297:185-9.
16. Rivers JK, Wolf J. Assessing clinically meaningful end points for the management of actinic keratoses with diclofenac 3% gel. Acta Derm Venereol 2007;87:188-9. (Pubitemid 46513216)
17. Rivers JK. Topical 3% diclofenac in 2.5% hyaluronan gel for the treatment of actinic keratoses. Skin Therapy Lett 2004;9:1-3.
18. Nelson C, Rigel D, Smith S, Swanson N, WolfJ. Phase IV, openlabel assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel. J Drugs Dermatol 2004;3:401-7.
19. Stockfleth E, Meyer T, Benninghoff B, Salasche S, Papadopoulos L, Ulrich C et al. A randomised, double blind, vehicle-controlled study to asses 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol 2002:138:1498-502. (Pubitemid 35315741)
20. Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomised, double blind, parallel group, vehicle controlled trials. J Am Acad Dermatol 2004;50:714-21.
21. Szeimies RM, Gerritsen MJ, Gupta G, Ortonne JP, Serresi S, Bichei et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double blind, vehicle-controlled clinical trial with histology. J Am Acad Dermatol 2004;51:547-55. (Pubitemid 39278073)
22. Korman N, Moy R, Ling M, Matheson R, Smith S, McKane S et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double blind, parallel group, vehicle-controlled trials. Arch Dermatol 2005;41:467-73.
23. Jorizzo J, Dinehart S, Matheson R, Moore JK, Ling M, Fox TL et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol 2007;57:265-8.
24. AlomarA, Bichei J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of Imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol 2007;157:133-41.
25. Hanke CW, Beer KR, Stockfleth E, Wu J, Rosen T, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol 2010;62:573-81.
26. Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol 2010;62:582-90.
27. Pariser DM, Lowe NJ, Stewart DM, Jarra MT, Lucky AW, Pariser RJ et al. Photodynamic therapy with topical methyl aminolevulinate (Metvix® is effective and safe in the treatment of actinic keratosis: results of a prospective randomized trial. J Am Acad Dermatol 2003;48:227-32.
28. Tarstedt M, Rosdahl I, Berne B, Svanberg K, Wennberg AM. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix®)-PDTin actinic keratosis of the face and scalp. Acta Derm Venereol (Stockh) 2005;85:424-8.
29. Szeimies RM, Karrer S, Radakovic-Fijan S, Tanew A, CalzavaraPinton PG, Zane C et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002;47:258-62.
30. Morton C, Campbell S, Gupta G, Keohane S, Lear J, Zaki I et al. Intraindividual, right-left comparison of topical methyl aminolaevulinate- photodynamic therapy (MAL-PDT) and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol 2006;155:1029-36.
31. Freeman M, Vinciullo C, Francis D, Spelman L, Nguyen R, Fergin P etal.A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix®) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatol Treat 2003;14:99-106.
32. Pariser D, Loss R, Jarratt M, Abramovits W, Spencer J, Geronemus R et al. Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: A randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 2008;59:569-76.
33. Szeimies RM, Matheson RT, Davis SA, Bhatia AC, Frambach Y, Klövekorn W et al. Topical methyl aminolevulinate photodynamic therapy using red light-emitting diode light for multiple actinic keratoses: a randomized study. Dermatol Surg 2009;35:586-92.
34. Kaufmann R, Spelman L, Weightman W, Reifenberger J, Szeimies RM, Verhaeghe E et al. Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol 2008;158:994-9.
35. Dragieva G, Prinz BM, Hafner J, Dummer R, Burg G, Binswanger U et al. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol 2004;151:196-200.
36. Wulf HC, Pavel S, Stender I, Bakker-Wensveen CA. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Derm Venereol 2006;86:25-8.
37. Piaserico S, Belloni Fortina A, Rigotti P, Rossi B, Baldan N, Alaibac M et al. Topical photodynamic therapy of actinic keratosis in renal transplant recipients. Transplant Proc 2007;39:1847-50.
38. Perrett CM, McGregor JM, Warwick J, Karran P, Leigh IM, Proby CM et al. Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br J Dermatol 2007;156:320-8.
39. Wennberg AM, Stenquist B, Stockfleth E, Keohane S, Lear JT, Jemec G et al. Photodynamic therapy with methyl aminolevulinate for prevention of new skin lesions in transplant recipients: a randomized study. Transplantation 2008;86:423-9.
40. Arks AH, van de Weert MM, Nelemans PJ, Kelleners-Smeets NW. Pain during topical photodynamic therapy: uncomfortable and unpredictable. J Eur Acad Dermatol Venereol 2010 Apr 26 [Epub ahead of print].
41. Briggs AH, Gray AM. Handling uncertainty in economic evaluations of healthcare interventions. BMJ 1999;319:635-8.
42. Muston D, Downs A, Rives V. An economic evaluation of topical treatments for actinic keratosis, J Dermatol Treat 2009;20: 266-75.
43. Caekelbergh K, Annemans L, Lambert J, Roelandts R. Economic evaluation of methyl aminolaevulinate-based photodynamic therapy in the management of actinic keratosis and basal cell carcinoma. Br J Dermatol 2006;155:784-90.
44. Evans C. The use of consensus methods and expert panels in phar"macoeconomic studies. Practical applications and methodological shortcomings. Pharmacoeconomics 1997;12:121-9.
45. Briggs AH, Mooney CZ, Wonderling DE. Constructing confidence intervals for cost-effectiveness ratios: an evaluation of parametric and non-parametric techniques using Monte Carlo simulation. Stat Med 1999;18:3245-62.
46. Drummond MF. The future of pharmacoeconomics: bridging science and practice. Clin Ther 1996;18:969-78.
47. Ellis CN, Reiter KL, Wheeler JR, Fendrick AM. Economic analysis in dermatology. J Am Acad Dermatol 2002;46:271-83.